Herpes Simplex Virus Type 1 Infection in Mice with Severe Combined Immunodeficiency (SCID)

  • Ryoichi Mori
  • Hiroko Minagawa
  • Shunji Sakuma
  • Shirou Mohri
  • Takeshi Watanabe
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 278)


For many years, the role of acquired immunity—that is, T lymphocytes and antibodies—in the protection against herpes simplex virus (HSV) has been our major interest. We have used neonatally thymectomized mice (1) and athymic nude mice (2) to study this, and others have used newborn mice (3), mice treated with antithymocyte sera (4), or mice treated with cyclophosphamide (5). In 1983 Bosma et al. (6) reported that they had observed a CB-17 inbred strain, BALB/c· C57BL/Ka-Igh-1b/ICR (N17F34), that had no detectable serum immunoglobulins, which has been found to be an inheritable defect under the control of a recessive gene (scid). These mice were also deficient in both Band T-lymphocyte functions, and were named severe combined immunodeficiency (SCID) mice. The newly developed immunologically deficient mouse strain attracted our attention as a good experimental model for systemic HSV infection in immunocompromised hosts.


Nude Mouse Dorsal Root Ganglion Herpes Simplex Virus Herpes Simplex Virus Type Spleen Cell 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mori, R., Tasaki, T., Kimura, G. and Takeya, K. (1967) Arch. Gesamte Virusforsch. 21, 459–462.PubMedCrossRefGoogle Scholar
  2. 2.
    Nagafuchi, S., Oda, H., Mori, R. and Taniguchi, T. (1979) J. Gen. Virol. 44, 715–723.PubMedCrossRefGoogle Scholar
  3. 3.
    Kilbourne, E. D. and Horsfall, F. L., Jr. (1951) J. Immunol. 67, 321–329.PubMedGoogle Scholar
  4. 4.
    Oakes, J. E. (1975) Infect. Immun. 12, 166–172.PubMedGoogle Scholar
  5. 5.
    Rager-Zisman, B. and Allison, A. C. (1976) J. Immunol 116, 35–40.PubMedGoogle Scholar
  6. 6.
    Bosma, G. C., Custer, R. P. and Bosma, M. J. (1983) Nature (London) 301, 527–530.CrossRefGoogle Scholar
  7. 7.
    Yoshino, K. and Taniguchi, S. (1969) Jpn. J. Exp. Merl 39, 223–232.Google Scholar
  8. 8.
    Otani, T. and Mori, R. (1987) Arch. Virol 96, 1–15.PubMedCrossRefGoogle Scholar
  9. 9.
    Hayashi, Y., Nagata, M., Yoshizumi, H., Mori, R., Navarro, C. V. and Yang H. D. (1984) Jpn. J. Med Sci. Biol. 37, 35–39.PubMedGoogle Scholar
  10. 10.
    Yasumoto, S., Okabe, N., Mori. R. (1986) Arch. Virol. 90, 261–271.PubMedCrossRefGoogle Scholar
  11. 11.
    Julis, M. H., Simpson, E., Herzenberg, L. A. (1973) Eur. J. Immunol. 3, 645–662.CrossRefGoogle Scholar
  12. 12.
    Lopez C. (1975) Nature (London) 258, 152–153.CrossRefGoogle Scholar
  13. 13.
    Minagawa, H., Sakuma, S., Mohri, S., Mori, R. and Watanabe, T. (1988) Arch. ViroL 103, 73–82.PubMedCrossRefGoogle Scholar
  14. A part of this article has been published as Minagawa, H., Sakuma, S., Mohri, S., Mori, R. and Watanabe, T. (1988) Arch. KroL 103, 73–82.Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Ryoichi Mori
    • 1
  • Hiroko Minagawa
    • 1
  • Shunji Sakuma
    • 1
  • Shirou Mohri
    • 2
  • Takeshi Watanabe
    • 3
  1. 1.Department of VirologyKyushu UniversityFukuoka 812Japan
  2. 2.Laboratory of Experimental Animals, School of MedicineKyushu UniversityFukuoka 812Japan
  3. 3.Department of Molecular Immunology, Medical Institute of BioregulationKyushu UniversityFukuoka 812Japan

Personalised recommendations